Published in Heart Rhythm on July 03, 2012
Adverse events following implantable cardioverter defibrillator implantation: a systematic review. J Interv Card Electrophysiol (2014) 0.81
Health care policy and regulatory implications on medical device innovations: a cardiac rhythm medical device industry perspective. J Interv Card Electrophysiol (2013) 0.78
Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention. Arrhythm Electrophysiol Rev (2012) 0.75
Perspectives in managing recalls of cardiac implantable electronic devices. Indian Pacing Electrophysiol J (2016) 0.75
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 19.43
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm (2007) 4.96
Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. JAMA (2001) 3.38
Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation (2010) 2.93
Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA (2006) 2.50
Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm (2010) 1.74
Multicenter experience with failed and recalled implantable cardioverter-defibrillator pulse generators. Heart Rhythm (2006) 1.74
Pacemaker and ICD generator reliability: meta-analysis of device registries. JAMA (2006) 1.62
Survival rates as a guide to implanted cardioverter-defibrillator replacement strategies for device recalls--adding statistical insight to clinical intuition. Am Heart J (2007) 0.88
Death due to an implantable cardioverter defibrillator. J Cardiovasc Electrophysiol (2004) 0.86
Pacemaker and ICD malfunction--an incomplete picture. JAMA (2006) 0.84
Small-diameter defibrillation electrodes: can they take a licking and keep hearts ticking? Heart Rhythm (2007) 0.83
Clinical significance of device-related complications in clinical trials and implications for future trials: insights from the Antiarrhytmics Versus Implantable Defibrillators (AVID) trial. Card Electrophysiol Rev (2003) 0.81
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm (2009) 5.17
Inflammation as a risk factor for atrial fibrillation. Circulation (2003) 4.95
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA (2005) 4.60
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Genome-wide association study of PR interval. Nat Genet (2010) 3.73
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest (2004) 3.63
Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med (2007) 3.61
Catheter ablation for atrial fibrillation. N Engl J Med (2011) 3.61
Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol (2010) 3.18
Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation (2010) 2.93
Delayed lead perforation: a disturbing trend. Pacing Clin Electrophysiol (2005) 2.92
Outcome of magnetic resonance imaging (MRI) in selected patients with implantable cardioverter defibrillators (ICDs). Pacing Clin Electrophysiol (2005) 2.86
Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation (2004) 2.79
Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation (2007) 2.78
Electrocardiographic imaging of cardiac resynchronization therapy in heart failure: observation of variable electrophysiologic responses. Heart Rhythm (2006) 2.73
Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension (2006) 2.64
Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation (2010) 2.57
Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. Circulation (2005) 2.56
Remote magnetic navigation: human experience in pulmonary vein ablation. J Am Coll Cardiol (2007) 2.56
Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol (2013) 2.43
Circular mapping and ablation of the pulmonary vein for treatment of atrial fibrillation: impact of different catheter technologies. J Am Coll Cardiol (2002) 2.42
Clinical study of the laser sheath for lead extraction: the total experience in the United States. Pacing Clin Electrophysiol (2002) 2.40
Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm (2009) 2.34
Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. Heart Rhythm (2009) 2.30
Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: impact on outcome and complications. Circulation (2003) 2.18
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA (2003) 2.16
Relationship between successful ablation sites and the scar border zone defined by substrate mapping for ventricular tachycardia post-myocardial infarction. J Cardiovasc Electrophysiol (2005) 2.12
Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol (2010) 2.11
Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome. Ann Intern Med (2003) 2.10
The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol (2007) 2.09
Noninvasive electroanatomic mapping of human ventricular arrhythmias with electrocardiographic imaging. Sci Transl Med (2011) 2.08
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08
Is defibrillation testing necessary for implantable transvenous defibrillators?: defibrillation testing is necessary at the time of implantable cardioverter defibrillator implantation. Circ Arrhythm Electrophysiol (2014) 2.07
Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo. Cardiovasc Res (2004) 2.04
Residual high incidence of ventricular arrhythmias after left ventricular reconstructive surgery. J Thorac Cardiovasc Surg (2005) 2.03
Atrial fibrillation ablation using a robotic catheter remote control system: initial human experience and long-term follow-up results. J Am Coll Cardiol (2008) 2.02
Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm (2009) 1.97
Percutaneous pericardial instrumentation for endo-epicardial mapping of previously failed ablations. Circulation (2003) 1.93
Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol (2004) 1.92
Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol (2005) 1.91
Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation (2010) 1.90
Focal atrial tachycardia after pulmonary vein isolation: noninvasive mapping with electrocardiographic imaging (ECGI). Heart Rhythm (2007) 1.88
Catheter cryoablation of supraventricular tachycardia: results of the multicenter prospective "frosty" trial. Heart Rhythm (2004) 1.86
Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol (2009) 1.86